Cerebrolysin 60mg
-
Detail
Cerebrolysin 60mg
Multi-Peptide Neurotrophic Complex | Porcine-Brain-Derived Neuropeptide Preparation
~25% Bioactive Peptides + ~75% Free Amino Acids · Lyophilized Powder · Research Use Only
🧠 Neurotrophic Mimicry
Peptide constituents designed to mimic endogenous neurotrophic factors — BDNF-like and NGF-like activity documented in research.
🔬 Multi-Target Action
Unlike single-pathway compounds, acts across neuroprotection, neurogenesis, synaptic plasticity and neuroinflammation pathways simultaneously.
📚 200+ Trials of Heritage
The cerebrolysin lineage is among the most extensively studied neuropeptide preparations, with decades of published research.
🧊 Standardized Extract
Enzymatic hydrolysis + purified extraction yields a reproducible peptide-amino-acid composition, supplied as stable lyophilized powder.
Product Overview
Cerebrolysin is a peptide-rich neuropeptide preparation produced by enzymatic hydrolysis and purified extraction of porcine brain protein. It is not a single molecule but a standardized complex: approximately 25% low-molecular-weight bioactive peptides (typically below 10 kDa, many under 3 kDa) and approximately 75% free amino acids.
The core scientific hypothesis behind cerebrolysin research is that its peptide constituents mimic the effects of endogenous neurotrophic factors — notably BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) — supporting neuronal survival, differentiation and synaptic plasticity. Because the preparation contains multiple active peptide species, it engages several neuroprotective pathways at once rather than a single receptor target.
Each vial contains 60mg of cerebrolysin preparation as a lyophilized powder, supplied for in-vitro and laboratory research use only.
Composition & Specifications
Product Name Cerebrolysin (Porcine-Brain-Derived Neuropeptide Preparation) Product Class Multi-component peptide/amino-acid complex — no single CAS number, sequence or molecular weight applies Peptide Fraction ≈ 25% low-molecular-weight bioactive peptides (predominantly < 10 kDa) Amino Acid Fraction ≈ 75% free amino acids — Asp, Glu, Ser, His, Gly, Thr, Ala, Arg, Val, Met, Trp, Ile, Phe, Leu, Lys, Pro Documented Peptide Constituents Active peptide species identified in the preparation include BDNF-like, NGF-like, enkephalin, orexin, CNGF and P21-related components (per published characterization studies) Source Material Porcine brain tissue, enzymatically hydrolyzed and purified Net Content 60 mg / vial Appearance Light yellow to off-white lyophilized powder Purity / Quality Control HPLC peptide profiling + composition verification per lot Solubility Soluble in water / aqueous buffer Storage Store lyophilized at 2–8°C or -20°C, protected from light and moisture; reconstituted solution: refrigerate and use promptly Mechanism of Action
🌱 Neurotrophic-factor mimicry — peptide constituents act as BDNF-like and NGF-like ligands, engaging TrkB and TrkA receptor pathways that maintain, protect and restore neuronal networks. 🛡 Neuroprotection — documented activity against excitotoxicity, oxidative stress and apoptotic signaling in neuronal cell and animal models. 🔗 Synaptic plasticity support — associated with improved synaptic function and neurite outgrowth in experimental systems. 🧩 Neurogenesis promotion — improved survival of neural stem cell grafts demonstrated in APP-transgenic Alzheimer's disease models (Rockenstein et al., 2015). 🔥 Neuroinflammation modulation — supports endogenous repair mechanisms and attenuates damaging inflammatory mediators in brain-injury models. Research Highlights
📖 Rockenstein et al., 2015 (Neurobiol Aging)
Neuro-peptide treatment with cerebrolysin improved the survival of neural stem cell grafts in an APP transgenic model of Alzheimer's disease — a key demonstration of its neurotrophic activity.
📖 Active-Peptide Identification Research (Yang et al., 2023)
Developed an optimized approach for identifying active peptides within cerebrolysin, cataloguing the neuroprotective peptide species that underpin its multi-target mechanism.
📖 Al-Kuraishy et al., 2025 (Neuroscience review)
Reviewed the possible role of cerebrolysin in managing neurodegenerative progression — summarizing evidence across Alzheimer's disease, cerebrovascular disease and stroke-recovery research.
Research Applications
🧠 Neuroprotection assays — excitotoxicity, oxidative-stress and apoptosis readouts in neuronal cell cultures. 🌱 Neurogenesis and neural-stem-cell survival studies, including Alzheimer's disease models. 🔗 Synaptic plasticity and neurite-outgrowth experiments. ⚡ Stroke-recovery and traumatic-brain-injury model research. 🧪 Multi-component natural-peptide characterization — active-fraction identification workflows. Evidence Status Note
📋 The cerebrolysin lineage has been evaluated in numerous clinical studies outside the United States, and the original pharmaceutical formulation holds marketing authorizations in multiple countries for dementia and stroke-recovery indications. This listing concerns the research-grade preparation only; individual research lots are not equivalent to any approved drug product, and all efficacy findings cited here are provided as scientific background for laboratory research.
Reconstitution & Handling
💧 Add sterile water or assay-compatible buffer slowly down the side of the vial; swirl gently until fully dissolved — do not shake vigorously. 🧪 As a multi-component mixture, working concentrations should be expressed as total preparation (mg/mL); aliquot to avoid repeated freeze-thaw cycles. 🧊 Store lyophilized powder cold, dry and protected from light; reconstituted solution: refrigerate and use within your validated stability window. 【请核实】 ⚖️ Handle with aseptic technique and appropriate PPE per your laboratory SOP. Because the source material is animal-derived, follow your institution's biological-material handling rules. Quality Assurance
✔ Lot-specific Certificate of Analysis: HPLC peptide-profile verification + amino-acid composition confirmation.
✔ Third-party batch testing documentation available upon request.
References & Further Reading
- Rockenstein E, et al. Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease. Neurobiol Aging. 2015. (PubMed: 26209890)
- Yang B, et al. Optimized approach for active peptides identification in cerebrolysin. J Chromatogr B. 2023.
- Al-Kuraishy HM, et al. The possible role of cerebrolysin in the management of neurodegenerative diseases. Neuroscience. 2025.
- Florek S, et al. Is Cerebrolysin useful in psychiatry disorders? PMC12292664. 2025.
- Current applications of Cerebrolysin® — review of clinical evidence base. Nesci.
Disclaimer: This product is a multi-component research preparation intended exclusively for in-vitro laboratory research use. It is not approved for human or animal use, is not a drug, food, cosmetic, or dietary supplement, and is not intended to diagnose, treat, cure or prevent any disease. Findings cited above are from published studies and do not constitute efficacy claims for any commercial product. All products are supplied strictly for research purposes only. -
Customer ReviewsNo comments